{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"87.20","value":"51.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The T1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal rate-constant (lambda\\[z\\]) of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 1.3 mg per m\\^2 of bortezomib on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.","id":"OG000","title":"Bortezomib"}],"paramType":"MEAN","populationDescription":"The PP population included all the participants who received study medications as per the administration schedule and for whom blood samples were collected at all scheduled time points.","reportingStatus":"POSTED","timeFrame":"0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1","title":"Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1","type":"PRIMARY","unitOfMeasure":"Hours"}